Zacks: Analysts Expect Translate Bio Inc (NASDAQ:TBIO) to Post -$0.42 Earnings Per Share

Brokerages expect Translate Bio Inc (NASDAQ:TBIO) to announce earnings of ($0.42) per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Translate Bio’s earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.56). Translate Bio reported earnings of ($0.13) per share in the same quarter last year, which would suggest a negative year over year growth rate of 223.1%. The firm is expected to announce its next quarterly earnings report on Thursday, March 19th.

According to Zacks, analysts expect that Translate Bio will report full-year earnings of ($1.80) per share for the current fiscal year, with EPS estimates ranging from ($2.26) to ($1.43). For the next fiscal year, analysts forecast that the company will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.48) to ($1.36). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Translate Bio.

Translate Bio (NASDAQ:TBIO) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.04. The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.77 million. Translate Bio had a negative net margin of 1,732.61% and a negative return on equity of 59.18%.

Several equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Translate Bio from a “sell” rating to a “hold” rating in a research report on Sunday, October 13th. Zacks Investment Research lowered shares of Translate Bio from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th. Citigroup set a $17.00 price objective on shares of Translate Bio and gave the stock a “buy” rating in a research report on Tuesday, September 10th. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Translate Bio in a research report on Thursday, August 1st. Finally, Jefferies Financial Group assumed coverage on shares of Translate Bio in a research report on Monday, July 22nd. They issued a “buy” rating and a $20.00 price objective for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $20.75.

Shares of NASDAQ TBIO opened at $9.63 on Tuesday. Translate Bio has a 1 year low of $4.81 and a 1 year high of $14.34. The company has a 50 day simple moving average of $9.20 and a 200-day simple moving average of $9.63. The company has a market capitalization of $564.81 million, a P/E ratio of -2.65 and a beta of 0.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.62 and a quick ratio of 8.62.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Artal Group S.A. grew its holdings in Translate Bio by 25.0% during the 2nd quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $9,473,000 after purchasing an additional 150,000 shares in the last quarter. Baupost Group LLC MA increased its stake in Translate Bio by 36.2% in the 2nd quarter. Baupost Group LLC MA now owns 8,844,239 shares of the company’s stock worth $109,372,000 after acquiring an additional 2,352,941 shares during the last quarter. Vanguard Group Inc. increased its stake in Translate Bio by 80.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,524,907 shares of the company’s stock worth $19,259,000 after acquiring an additional 680,330 shares during the last quarter. Magnus Financial Group LLC bought a new position in Translate Bio in the 2nd quarter worth about $895,000. Finally, McGuire Investment Group LLC bought a new position in Translate Bio in the 3rd quarter worth about $101,000. 64.85% of the stock is owned by institutional investors and hedge funds.

About Translate Bio

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Recommended Story: What is diluted earnings per share (Diluted EPS)?

Get a free copy of the Zacks research report on Translate Bio (TBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.